Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Respiratory System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Respiratory System Neoplasm

Cancer Family

Respiratory System Neoplasm

CI-CAN-00000049Explore in graph →

Non-malignant2,727 active trials51 approved drugs619 evidence items

NCIt: C3355
MeSH: D012142

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11611
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
· J Clin Oncol · 2016 · PMID 27022118 · validated civic_curation pubmed
Ceritinib in ALK-rearranged non-small-cell lung cancer.
· N Engl J Med · 2014 · PMID 24670165 · validated civic_curation pubmed
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
· Lancet Oncol · 2014 · PMID 25153538 · validated civic_curation pubmed
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
· Nat Med · 2012 · PMID 22426421 · validated civic_curation pubmed
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
· Cancer · 2013 · PMID 22810899 · validated civic_curation pubmed
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
· Lancet Oncol · 2016 · PMID 27083334 · validated civic_curation pubmed
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

Showing 176–200 of 483 publications

← Previous
1
…
7
8
9
…
20
Next →

· Lung Cancer · 2013 · PMID 24035188 · validated civic_curation pubmed

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

· J Thorac Oncol · 2011 · PMID 21258250 · validated civic_curation pubmed

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

· Lancet Oncol · 2012 · PMID 22452896 · validated civic_curation pubmed

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

· J Clin Oncol · 2010 · PMID 20038723 · validated civic_curation pubmed

The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.

· Cancer Biomark · 2013 · PMID 24595080 · validated civic_curation pubmed

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

· Lancet Oncol · 2012 · PMID 22285168 · validated civic_curation pubmed

Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

· Clin Cancer Res · 2011 · PMID 21531810 · validated civic_curation pubmed

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

· J Clin Oncol · 2017 · PMID 28475456 · validated civic_curation pubmed

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

· Ann Oncol · 2015 · PMID 25722381 · validated civic_curation pubmed

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

· Ann Oncol · 2016 · PMID 26802155 · validated civic_curation pubmed

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

· N Engl J Med · 2004 · PMID 15118073 · validated civic_curation pubmed

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

· Ann Oncol · 2015 · PMID 26209642 · validated civic_curation pubmed

Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.

· PLoS One · 2014 · PMID 24647522 · validated civic_curation pubmed

Pembrolizumab for the treatment of non-small-cell lung cancer.

· N Engl J Med · 2015 · PMID 25891174 · validated civic_curation pubmed

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted

· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed

EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.

· J Investig Med · 2017 · PMID 27664271 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

· Cancer Discov · 2018 · PMID 29773717 · validated civic_curation pubmed

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

· Lancet Oncol · 2011 · PMID 21783417 · validated civic_curation pubmed